Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges [PDF]
BiomoleculesHypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj +2 more sources
Cardiac Myosin Inhibitors (CMIs) and Surgical Referral in Patients with Hypertrophic Cardiomyopathy [PDF]
Journal of Cardiovascular Development and DiseaseThe management of obstructive hypertrophic cardiomyopathy (HCM) has been transformed by the advent of cardiac myosin inhibitors (CMIs), such as mavacamten and aficamten.
Benedetto Ferraresi +9 more
doaj +2 more sources
A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions [PDF]
The Journal of Clinical InvestigationThe myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility.
Julius Bogomolovas, Ju Chen
doaj +2 more sources
Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort [PDF]
Reviews in Cardiovascular MedicineBackground: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr +7 more
doaj +2 more sources
Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
Frontiers in Physiology, 2022 Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death.
Masataka Kawana +3 more
doaj +1 more source
Azidoblebbistatin, a photoreactive myosin inhibitor [PDF]
Proceedings of the National Academy of Sciences, 2012 Photoreactive compounds are important tools in life sciences that allow precisely timed covalent crosslinking of ligands and targets. Using a unique technique we have synthesized azidoblebbistatin, which is a derivative of blebbistatin, the most widely used myosin inhibitor.
M. Kepiro +6 more
openaire +2 more sources
Cardiac myosin inhibitors in hypertrophic cardiomyopathy: advancing care with caution. [PDF]
Ann Med Surg (Lond)Rehman Z +4 more
europepmc +3 more sources
Small-Molecule Inhibitors of Myosin Proteins [PDF]
Future Medicinal Chemistry, 2012 Advances in screening and computational methods have enhanced recent efforts to discover/design small-molecule protein inhibitors. One attractive target for inhibition is the myosin family of motor proteins. Myosins function in a wide variety of cellular processes, from intracellular trafficking to cell motility, and are implicated in several human ...
Bond, L.M. +3 more
openaire +3 more sources
The Formin Inhibitor, SMIFH2, Inhibits Members of the Myosin Superfamily [PDF]
Biophysical Journal, 2020 Abstract The small molecular inhibitor of formin FH2 domains, SMIFH2, is widely used in cell biological studies. It was selected in a chemical screen as a compound inhibiting formin-driven actin polymerization in vitro , but not polymerization of pure actin, and found to be active ...
Yukako Nishimura +7 more
openaire +4 more sources
Enhanced tumor cell killing by ultrasound after microtubule depolymerization
Bioengineering & Translational Medicine, 2021 Recent studies show that tumor cells are vulnerable to mechanical stresses and undergo calcium‐dependent apoptosis (mechanoptosis) with mechanical perturbation by low‐frequency ultrasound alone.
Aditi Singh +6 more
doaj +1 more source